NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF REPEAT MEDICINES, APPLIANCES AND ACBS PRODUCTS.

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS.

# IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE MOST UP TO DATE PGD

# 1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

Physician	Dr George Crooks	Signature		
Pharmacist	Dr John McAnaw	_ Signature		
NHS Scotland Representative	John Turner	_ Signature		
Authorised for use	on behalf of			Health Board by
Medical Director		_ Signature		
Senior Pharmacist		_ Signature		
Clinical Governance Lead		Signature		
		_		
Date Approved				
Effective from			Expires	
Unscheduled Care – Pha Due for review April 2012 NOT FOR AMENDMEN		12 Section 11	from Octo	ober 2011 - October 2012. Page 1 of 23

It is the responsibility of the individual to ensure they are using the most up to date PGD.

Urgent Provision Of Current Repeat Prescribed Medicines, Appliances And ACBS Products.

# 2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

# 3. Application

This PGD covers the urgent provision of current repeat NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists when the patient's prescriber is unavailable; the surgery is closed or if an out-of-hours system is in operation.

# 4. Clinical Condition

Situation	The provision from a pharmacy with an NHS contract of repeat NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for further supplies in the normal way for the clinical conditions listed in schedules 1 to 15 of this PGD.	
Inclusion Criteria	Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber. The requirement to interview the patient directly prior to a supply being made will be removed in the case of an announcement of a pandemic or imminent pandemic (WHO level 6).	
	Medicines and/or appliances and/or ACBS products are allowed on NHS prescription.	
	Surgery is closed and/or prescriber unavailable.	
	Patient is registered (or temporarily) with a medical practice in Scotland.	
	Patient agrees to relevant clinical information being provided to the pharmacist.	
Exclusion Criteria	Provision is not urgent.	
	Patient's medicines and/or appliances and/or ACBS products are not on repeat prescription.	
	Medicines and/or appliances and/or ACBS products are not allowed on NHS prescription.	
	No agreement to share relevant clinical information.	
	Urgent provision for the medicines and/or appliances and/or ACBS products requested at last prescribing cycle. Patient's clinical condition significantly changed.	
Action if Excluded	Pharmacist's judgement to provide supply under existing emergency supply regulations.	
Unscheduled Care – Pharmacy C Due for review April 2012	Guide - PGD-Version 12from October 2011 - October 2012.Section 11Page 2 of 23	

NOT FOR AMENDMENT.

Referral to Prescriber	Significant change in clinical condition.	
	Any relevant reason by pharmacist.	

# 5. Description of Treatment

Medicine	All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in the schedules to this PGD.
Legal Status	As described in the BNF or BNFC.
Dosage Form and Strength	As normally prescribed by the patient's prescriber.
ottongth	ог
	Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.
Dose	As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC.
Exceptions	As listed in the Annexes to this PGD.
Duration of Supply	One prescribing cycle i.e. quantity and duration normally prescribed to the patient or up to one months supply if not known.
Patient Information	Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet.
	Provision of any other relevant information as judged by the pharmacist operating under this PGD.
Documentation	The pharmacist will complete a CP(US) in accordance with the requirements contained in the guidance to this PGD.
Supply	The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging.
Follow-up	Ensure that the patient's prescriber is notified and that all records are complete and CP(US) is forwarded to NHS NSS.
Adverse reactions	As described in BNF or BNFC.
Patient Charges	Normal charge equivalent to that applied to an NHS prescribed item and current NHS exemptions are applicable.

Record/Audit Trail	The CP(US) should be forwarded to NHS NSS for onward processing.
	A record of the transaction i.e. a fax or photocopy of the CP(US) should be forwarded to the patient's Prescriber as soon as possible.
	A record of the transaction should be entered in the patient's Prescription Medication Record.

#### 6. Characteristic of Staff

Qualifications	Pharmacist whose name is currently on the practising section of
Required	the pharmaceutical register held by the General Pharmaceutical
	Council.

# PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Gastro-Intestinal System Section 1

**Part A:** All medicines except those contained in Part B of this Schedule listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Abdominal colic/distension	Faecal incontinence	Management of colostomy and ileostomy patients
Anal fissures	Fistulas	Pancreatic disorders
Bowel colic	Food allergy	Primary biliary cirrhosis
Conditions requiring gastric acid reduction	Gastrectomy	Proctitis
Constipation	Gastritis	Proctosigmoiditis
Crohn's disease	Gastro-oesophageal reflux disease	Pruritus
Cystic fibrosis	Gastroprotection	Reflux oesophagitis
Diarrhoea	Gustatory sweating	Short bowel syndrome
Dissolution of gall stones	Haemorrhoids	Smooth muscle spasm
Diverticular disease	Hepatic encephalopathy	Ulcerative colitis
Dysmenorrhoea	Infant colic	Ulceration including duodenal; gastric; stomal; stress; NSAID associated
Dyspepsia	Inflammatory bowel disease	Wind pain
Excessive respiratory secretions	Irritable bowel syndrome	Zollinger – Ellison syndrome

**Part B:** The following medicines listed in Gastro-Intestinal System, section 1 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
1.2	All injections	Acute use only
1.3	All <sup>1</sup>	Diagnostic use only
1.3.1	All injections	Acute use only
1.3.5	All injections and infusions	Acute use only
1.5.3	All injections and infusions	Specialist use only
1.6.5	All	Acute use only
1.7.3	All	Acute use only

 <sup>&</sup>lt;sup>1</sup> All H.pylori tests are excluded, please refer to each individual sub section for all other exclusions.

 Unscheduled Care – Pharmacy Guide - PGD-Version 12
 from October 2011 - October 2012.

 Due for review April 2012
 Section 11
 Page 5 of 23

 NOT FOR AMENDMENT.
 It is the responsibility of the individual to ensure they are using the most up to date PGD.
 Vertical and the provided of the provided of the individual to ensure they are using the most up to date PGD.

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Cardiovascular System Section 2

**Part A:** All medicines except those contained in Part B of this Schedule listed in Cardiovascular System, section 2 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acute coronary syndrome	Hyperlipidaemias	Phaeochromocytoma
Angina	Hypertension	Portal hypertension
Anxiety	Hyperthyroidism	Prevention of MI and stroke
Arrhythmias	Hypertriglyceridaemia	Primary hyperaldosteronism
Ascites	Hypertrophic cardiomyopathy	Prophylaxis of embolisation
Cerebrovascular disease	Intermittent claudication	Pulmonary hypertension
Coronary artery disease	Left ventricular dysfunction	Raynaud's syndrome
Coronary heart disease	Menopausal flushing	Renal complications
Diabetic nephropathy	Menorrhagia	Sitosterolaemia
Dyslipidaemia	Migraine prophylaxis	Systemic sclerosis
Essential tremor	Myocardial infarction	Thromboembolic disease
Fibrinolysis	Nephrotic syndrome	Thyrotoxicosis
Heart failure	Occlusive arterial disease	Transient ischaemic attack
Hereditary angioedema	Oedema	
Hypercholesterolaemia	Peripheral vascular disease	

Urgent Provision Of Current Repeat Prescribed Medicines, Appliances And ACBS Products.

**Part B:** The following medicines listed in Cardiovascular System, section 2 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
2.1.1	All injections	Acute use only
2.1.2	All	Acute use only
2.2.2	All injections	Acute use only
2.2.5	All	Acute use only
2.3.2	All injections	Acute use only
	Mexiletine	
	Amiodarone sterile concentrate	
2.4	All injections	Acute use only
2.5.1	Ambrisentan	Specialist use only
	Bosentan	
	All injections and infusions	Acute use only
	lloprost	Specialist use only
	Sildenafil	
2.5.2	All injections	Acute use only
2.5.3	All	Acute use only
2.5.4	Phenoxybenzamine hydrochloride	Acute use only
	All injections	
2.6.1	All injections	Acute use only
2.6.2	Nimodipine	Acute use only
	All injections	
2.7 + all subsections	All	Acute use only
2.8.1	Heparin	Specialist use only
	Danaparoid	
	Bivalirudin	
	Lepirudin	
	Heparin flushes	
	Epoprostenol	
	Fondaparinux sodium	
2.8.2	Dabigatran etexilate	Specialist use only
	Rivaroxaban	Acute use only
2.8.3	All	Acute use only
2.9	All injections and infusions	Specialist use only
2.10.2	All	Acute use only
2.11	All injections	Acute use only
	All blood products	Specialist use only
2.13	All	Acute use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Respiratory System Section 3

**Part A:** All medicines except those contained in Part B of this Schedule listed in Respiratory System, section 3 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic disorders	Cough	Pruritus
Anaphylactic reactions	Cystic fibrosis	Reduction of sputum viscosity
Asthma	Hypoxaemia	Reversible airways obstruction
Bronchial secretion expulsion	Migraine	Rhinitis
Chronic obstructive pulmonary disease	Nasal congestion	Urticaria

**Part B:** The following medicines listed in Respiratory System, section 3 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
3.1.1.1	All injections and infusions	Acute use only
3.1.1.2	All injections	Acute use only
3.1.3	All injections	Acute use only
3.4.1	All injections	Acute use only
3.4.2	All	Specialist use only
3.4.3	All except Anapen, Epipen and Jext injections for self administration	Acute use only
3.5 + all subsections	All	Specialist use only
3.7	Erdosteine	Acute use only
3.9.1	Codeine phosphate Methadone hydrochloride Morphine hydrochloride	Potential for abuse Controlled drug

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Central Nervous System Section 4

**Part A:** All medicines except those contained in Part B of this Schedule listed in Central Nervous System, section 4 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Aggressive, violent, dangerously impulsive or self-mutilating behaviour	Generalised anxiety disorder	Obsessive compulsive disorder
Agitation and restlessness	Headache	Pain
Alcohol dependence	Hypersalivation	Panic disorders
Alcohol withdrawal	Infantile spasms	Parkinson's disease
Anxiety	Insomnia	Phobic and obsessional states
Attention deficit hyperactivity disorder	Intractable hiccup	Post-traumatic stress disorder
Bipolar disorder	Labyrinthine disorders	Psychomotor agitation
Bulimia nervosa	Mania	Pyrexia
Cataplexy associated with narcolepsy	Meniere's disease	Restless legs syndrome
Childhood autism	Menopausal flushing	Schizophrenia and other psychoses
Choreas	Migraine	Sedation
Dementia	Motion sickness	Seizures
Depression	Motor neurone disease	Sleep disorders
Deviant antisocial sexual behaviour	Motor tics	Smoking cessation
Drug-induced extra- pyramidal symptoms	Movement disorders	Social anxiety disorder
Dysmenorrhoea	Myoclonus	Status epilepticus
Dyspepsia & GORD	Narcolepsy	Tinnitus
Epilepsy	Nausea and vomiting	Tourette syndrome
Essential tremor	Neuropathic pain	Vertigo
Excitement	Nocturnal enuresis	Vestibular disorders
Febrile convulsion	Obesity	

**Part B:** The following medicines listed in Central Nervous System, section 4 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
4.1.1	Temazepam Sodium oxybate Melatonin	Controlled drug Specialist use only Acute use only
4.1.2	All injections Meprobamate	Acute use only Controlled drug
4.1.3	All	Controlled drug
4.2.1	All injections Clozapine <sup>2</sup>	Acute use only Registration required
4.4	Dexamfetamine Methylphenidate Cocaine	Controlled drug
4.5.2	Diethylpropion Phentermine	Controlled drug
4.6	All injections Aprepitant Nabilone	Acute use only
471		Specialist use only
4.7.1 4.7.2	Paracetamol infusion         All injections         Buprenorphine         Diamorphine hydrochloride         Dipipanone hydrochloride         Fentanyl         Hydromorphone hydrochloride         Methadone hydrochloride         Morphine salts <sup>3</sup> Oxycodone hydrochloride         Oxycodone hydrochloride with         naloxone         Pentazocine         Pethidine hydrochloride         Tapentadol	Acute use only Acute use only Controlled drug
4.7.4.2	Methysergide	Specialist use only
4.8.1	All injections and infusions Clobazam <sup>4</sup> Phenobarbital	Acute use only Epilepsy only Controlled drug
4.8.2	All injections	Acute use only
4.9.3	Botulinum toxin type A and B	Specialist use only
4.10.3	Buprenorphine Buprenorphine with naloxone Methadone hydrochloride Lofexidine hydrochloride Naltrexone hydrochloride	Controlled drug Acute use only Potential for abuse

<sup>&</sup>lt;sup>2</sup> Clozapine can be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that patient.

<sup>4</sup> Clobazam can be supplied under the PGD for <u>epilepsy only and must be endorsed SLS.</u>

Unscheduled Care – Pharmacy Guide - PGD-Version 12from October 2011 - October 2012.Due for review April 2012Section 11NOT FOR AMENDMENT.Page 10 of 23

<sup>&</sup>lt;sup>3</sup> All strengths are not allowed on the PGD including oramorph 10mg/5ml.

It is the responsibility of the individual to ensure they are using the most up to date PGD.

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Infections Section 5

**Part A:** All medicines except those contained in Part B of this Schedule listed in Infections, section 5 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Leprosy	Tuberculosis treatment and chemoprophylaxis
Bacterial infection	Lyme arthritis	Viral infection
Dermatitis herpetiformis	Rheumatic fever	
Fungal infection	Rosacea	

**Part B:** The following medicines listed in Infections, section 5 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
5.1 + all subsections	All injections and infusions and nebuliser solutions	Acute use only
5.2 + all subsections	All injections and infusions	Acute use only
5.3.1	All	Specialist use only
5.3.2 + all subsections	All infusions	Acute use only
5.3.3	All	Specialist use only
5.3.4	All	Acute use only <sup>5</sup>
5.3.5	All	Specialist use only
5.4 + all subsections	All	Acute use only
5.5 + all subsections	All	Acute use only

 <sup>&</sup>lt;sup>5</sup> Refer to emergency planning section for distribution arrangements in the case of pandemic flu.

 Unscheduled Care – Pharmacy Guide - PGD-Version 12
 from October 2011 - October 2012.

 Due for review April 2012
 Section 11
 Page 11 of 23

 NOT FOR AMENDMENT.
 It is the responsibility of the individual to ensure they are using the most up to date PGD.
 PGD-Version 12

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

# **BNF/BNFC Class of Medicine**

#### Endocrine System Section 6

**Part A:** All medicines except those contained in Part B of this Schedule listed in Endocrine System, section 6 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acromegaly	Hashimoto's thyroiditis	Menstrual disorders
Addison's disease	Hereditary angioedema	Neuropathic oedema
Adrenocorticol insufficiency	Hormone replacement therapy	Nocturia
Benign fibrocystic breast disease	Hyperprolactinaemia	Nocturnal enuresis
Benign prostatic hyperplasia	Hyperthyroidism	Osteolytic lesions
Blood glucose monitoring	Hypoglycaemia	Osteoporosis
Bone metastases (reduction of bone damage)	Hypogonadism	Pagets disease
Breast pain	Hypopituitarism	Polycystic ovary syndrome
Congenital adrenal hyperplasia	Hypothyroidism	Postmenopausal symptoms
Diabetes insipidus	Inappropriate secretion of antidiuretic hormone	Postnatal depression
Diabetes mellitus	Infertility	Postponement of menstruation
Diffuse non-toxic goitre	Inflammatory and allergic disorders	Premenstrual syndrome
Dysfunctional uterine bleeding	Insulin-like growth factor-l deficiency	Prolactinoma
Dysmenorrhoea	Juvenile myxoedema	Recurrent miscarriage
Endometriosis	Male hypersexuality and sexual deviation	Thyroid carcinoma
Galactorrhoea	Menopausal symptoms	Urinalysis
Haemophilia	Menorrhagia	von Willebrand's disease

Urgent Provision Of Current Repeat Prescribed Medicines, Appliances And ACBS Products.

**Part B:** The following medicines listed in Endocrine System, section 6 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
6.1.6	Anhydrous glucose	Acute use only
6.2.1	All injections	Acute use only
6.2.2	lodine and iodide	Acute use only
6.3.2	All injections and infusions	Acute use only
6.4.1.1	Estradiol implant	Time period between repeats
6.4.1.2	All injections	Specialist use only
6.4.2	Testosterone and esters Mesterolone	Controlled drug
6.4.3	All	Controlled drug
6.5.1	All	Specialist use only
6.5.2	All injections	Acute use only
6.6.1	Calcitonin injection	Specialist use only
6.6.2	All injections and infusions	Specialist use only
6.7.2	All injections	Specialist use only
6.7.3	All	Specialist use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

# BNF/BNFC Class of Medicine Obstetrics, Gynaecology and Urinary Tract Disorders Section 7

**Part A:** All medicines except those contained in Part B of this Schedule listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Benign prostatic hyperplasia	Menopausal disorders	Urinary retention
Bladder spasms	Menstrual disorders	Urinary urgency
Contraception	Neurogenic bladder	Urological pain
	instability	
Dysuria	Nocturnal enuresis	Urolithiasis
Enuresis	Postmenopausal symptoms	Vaginal & vulval infections
Erectile dysfunction	Urinary frequency	Vaginal atrophy
Hormone replacement	Urinary incontinence	
therapy		

**Part B:** The following medicines listed in Obstetrics, Gynaecology and Urinary Tract Disorders, section 7 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
7.1 + all subsections	All	Specialist use only
7.3.2.2	Etonogestrel implant	Time period between repeats
7.3.2.3	All	Time period between repeats
7.3.4	All	Time period between repeats
7.3.5	All	Acute use only
7.4.4	All	Specialist use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

# Malignant Disease and Immunosuppression Section 8

**Part A:** All medicines except those contained in Part B of this Schedule listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anovulatory infertility	Cancer	Nephrotic syndrome
Autoimmune conditions	Graft-versus-host disease	Organ transplantation
Bone-marrow transplantation	Mastalgia	

**Part B:** The following medicines listed in Malignant Disease and Immunosuppression, section 8 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
8.1 + all subsections	All	Specialist use only
8.2.1	All injections and infusions	Specialist use only
8.2.2	All injections and infusions	Specialist use only <sup>6</sup>
8.2.3	All	Specialist use only
8.2.4	All	Specialist use only
8.3.4.1	Fulvestrant	Specialist use only
8.3.4.2	Buserelin injection Goserelin Histrelin Leuprorelin acetate Triptorelin Degarelix	Specialist use only
8.3.4.3	All	Specialist use only

<sup>6.</sup> Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Nutrition and Blood Section 9

**Part A:** All medicines except those contained in Part B of this Schedule listed in Nutrition and Blood, section 9 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anaemias	Isoniazid neuropathy	Scleroderma
Autoimmune hepatitis	Leber's optic atrophy	Selenium deficiency
Calcium deficiency	Metabolic disorders	Sickle-cell disease
Chronic acidotic states	Oral nutrition	Sodium depletion
Cystinuria	Peyronie's disease	Thrombocythaemia
Fluid and electrolyte loss	Potassium depletion	Tobacco amblyopia
Hypercalcaemia	Premenstrual syndrome	Vitamin deficiency states
Hyperparathyroidism	Prevention of methotrexate	Wilson's disease
	induced side effects	WIISON'S UISEASE
Hyperphosphataemia	Prevention of neural tube	Zinc deficiency
riyperpriospriataerrita	defects	
Hypophosphotoomia	Prophylaxis in chronic	
Hypophosphataemia	haemolytic states	
Iron overload	Prophylaxis of dental caries	
	FIOPHYIAXIS OF DEFILAT CALLES	

**Part B:** The following medicines listed in Nutrition and Blood, section 9 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
9.1.1.2	All	Specialist use only
9.1.2	Folic acid injection	Acute use only
9.1.3	Antilymphocyte immunoglobulin Oxymetholone Desferrioxamine mesilate Eculizumab	Specialist use only Controlled drug Specialist use only
9.1.4	All injections Eltrombopag	Specialist use only
9.1.6	All	Specialist use only
9.1.7	All	Specialist use only
9.2.1.1	Polystyrene sulphonate resins	Specialist use only
9.2.2.1	All EXCEPT Water for Injections	Acute use only
9.2.2.2	All	Specialist use only

Urgent Provision Of Current Repeat Prescribed Medicines, Appliances And ACBS Products.

Sub Section	Excluded Drugs	Rationale
9.3	All	Specialist use only
9.5.1+ all subsections	All injections and infusions	Acute use only
9.5.2.1	All infusions	Acute use only
9.5.4	All injections	Acute use only
9.5.5	All injections	Acute use only
9.6.2	All injections	Acute use only
9.6.3	All injections	Acute use only
9.6.4	All injections	Acute use only
9.6.6	All injections	Acute use only
9.8.1	Carnitine injection Agalsidase alfa and beta Imiglucerase Velaglucerase alfa Galsulfase Idursulfase Laronidase Mercaptamine Alglucosidase alfa Nitisinone Carglumic acid Sodium phenylbutyrate Betaine Miglustat	Specialist use only
9.8.2	All	Acute use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

# Musculoskeletal and Joint Diseases Section 10

**Part A:** All medicines except those contained in Part B of this Schedule listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Ankylosing spondylitis	Leg cramps	Polymyositis
Dermatological conditions aggravated or caused by sunlight	Menorrhagia	Post-herpetic neuralgia
Diabetic neuropathy	Migraine	Prophylaxis of familial mediterranean fever
Dysmenorrhoea	Muscle spasm	Psoriatic arthritis
Gout	Muscle spasticity	Renal stones
Hyperuricaemia	Musculoskeletal disorders	Rheumatic disease
Immunosuppression	Myasthenia gravis	Rheumatoid arthritis
Inflammation	Osteoarthritis	Soft-tissue disorders
Juvenile arthritis	Pain	Systemic and discoid lupus erythematosus

**Part B:** The following medicines listed in Musculoskeletal and Joint Diseases, section 10 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
10.1.1	All injections and infusions	Acute use only
10.1.2.2	All	Specialist use only
10.1.3	All injections and infusions Leflunomide <sup>6</sup>	Specialist use only Monitoring required <sup>6</sup>
10.1.4	Probenecid	Specialist use only
	Rasburicase	Acute use only
10.2.1	All injections	Specialist use only
10.2.2	All injections	Specialist use only
	Amifampridine	
	Cannabis Sativa Extract	Controlled drug
10.3.1	All	Acute use only
10.3.2	Capsaicin patches	Specialist use only

<sup>&</sup>lt;sup>6</sup> Leflunomide can be supplied under the PGD if the patient is within the required monitoring period

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Eye Section 11

**Part A:** All medicines except those contained in Part B of this Schedule listed in Eye, section 11 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic conjunctivitis	Epilepsy	Ocular hypertension
Anterior uveitis	Glaucoma	Raised intra-ocular pressure
Chronic eye infections	Inflammation	Seasonal keratoconjunctivitis
Corneal ulcers	Miosis	Tear deficiency
Dry eye conditions	Mydriasis	Vernal keratoconjunctivitis

**Part B:** The following medicines listed in Eye, section 11 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
11.3.2	All	Specialist use only
11.4.1	Loteprednol etabonate Dexamethasone Intravitreal Implant	Acute use only Specialist use only
11.5	Tropicamide Phenylephrine hydrochloride	Acute use only
11.6	All injections	Specialist use only
11.7	All	Acute use only
11.8.1	Balanced salt solution	Acute use only
11.8.2	Fluorescein sodium Acetylcholine chloride Apraclonidine Pegaptanib Ranibizumab Verteporfin	Specialist use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Ear, Nose and Oropharynx Section 12

**Part A:** All medicines except those contained in Part B of this Schedule listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Chronic otitis media	Nasal staphylococcal eradication	Painful inflammatory conditions of the oropharynx
Denture stomatitis	Oral and perioral infections	Post irradiation mucositis
Dry mouth	Oral and perioral lesions	Rhinitis
Inflammatory conditions of the nose	Oral hygiene	Sjogren's syndrome
Nasal infections	Oral ulceration and inflammation	Symptomatic relief of oral pain
Nasal polyps	Otitis externa (infection or inflammation)	

**Part B:** The following medicines listed in Ear, Nose and Oropharynx, section 12 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
12.1.1	Aluminium acetate	Acute use only
12.1.3	All	Acute use only
12.2.2	Ephedrine hydrochloride Xylometazoline hydrochloride	Acute use only
12.3.1	Flurbiprofen	Acute use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

# **BNF/BNFC Class of Medicine**

#### Skin Section 13

**Part A:** All medicines except those contained in Part B of this Schedule listed in Skin, section 13 of the current BNF/BNFC may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Acne vulgaris	Herpes	Rosacea
Actinic keratosis	Hirsuitism	Scalp disorders
Bacterial and viral infections	Hyperhidrosis	Skin disfigurement
Bruising	Hyperkeratotic skin disorders	Skin disinfection and cleansing
Chilblains	lleostomy and colostomy care	Skin protection
Corns and calluses	Inflamed or damaged skin disorders	Skin ulcers
Cradle cap	Malodorous fungating tumours	Superficial basal cell carcinoma
Dermatitis	Minor wounds, minor burns and abrasions	Superficial thrombophlebitis
Dry and eczematous skin disorders	Nappy rash	Urinary rash
Fissures	Photosensitivity	Varicose ulcers
Fistulae	Pressure sores	Varicose veins
Fungal nail infections	Pruritic skin conditions	Warts and verrucas
Fungal skin infections	Psoriasis	

**Part B:** The following medicines listed in Skin, section 13 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
13.3	Topical local anaesthetics Topical antihistamines	Acute use only
12.5.1		Creatialist use anhy
13.5.1	Alitretinoin	Specialist use only
13.5.2	Acitretin	Specialist use only
13.5.3	All injections and infusions	Specialist use only
13.6.2	Isotretinoin	Specialist use only
13.7	Podophyllotoxin	Specialist use only
13.10.1.1	Retapamulin	Acute use only
13.10.4	All	Acute use only
13.10.5	All skin tissue adhesives	Acute use only
13.12	Glycopyrronium bromide	Specialist use only

# PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Immunological Products and Vaccines Section 14

**Part A:** All medicines except those contained in Part B of this Schedule listed in Immunological Products and Vaccines, section 14 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

**Part B:** The following medicines listed in Immunological Products and Vaccines, section 14 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
Chapter 14	All	Specialist use only

#### PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT REPEAT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

#### **BNF/BNFC Class of Medicine**

#### Anaesthesia Section 15

**Part A:** All medicines except those contained in Part B of this Schedule listed in Anaesthesia, section 15 BNF may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Local anaesthesia	Pain relief	Postherpetic neuralgia

**Part B:** The following medicines listed in Anaesthesia, section 15 of the current BNF/BNFC may not be provided under this PGD.

Sub Section	Excluded Drugs	Rationale
15.1 + all subsections	All	Acute use only
15.2	All injections and infusions Lidocaine solution Lidocaine spray Lidocaine with phenylephrine solution	Acute use only
	Cocaine	Controlled drug